LabCorp And Myriad Genetics Form Exclusive Predictive Medicine Marketing Alliance

BURLINGTON, N.C. and SALT LAKE CITY, Utah, Dec. 4 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) and Myriad Genetics, Inc. (Nasdaq: MYGN), today announced their new partnership to make Myriad's predictive medicine products broadly available to primary care

LabCorp(R) Scheduled to Present at Credit Suisse First Boston Health Care Conference

BURLINGTON, N.C., Nov. 14 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced that Thomas P. Mac Mahon, chairman and chief executive officer, is scheduled to speak at the CSFB Health Care Conference in Phoenix, AZ on Thursday, November 15 at 9:30

LabCorp(R) Scheduled to Present at CIBC World Markets 12th Annual Health Care Conference

BURLINGTON, N.C., Nov. 5 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced that Thomas P. Mac Mahon, chairman and chief executive officer, is scheduled to speak at the CIBC World Markets 12th Annual Health Care Conference in New York City, NY on

Laboratory Corporation of America(R) Announces Third Quarter Results; Growth Strategy Continues to Drive Volume and Price Increases

BURLINGTON, N.C., Oct. 22 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced results for the quarter ended September 30, 2001. Third Quarter Results Net sales were $560.9 million, operating income was $100.3 million, and net income was $51.2

LabCorp(R) Scheduled to Present at UBS Warburg Global Life Sciences Conference

BURLINGTON, N.C., Oct 10, 2001 /PRNewswire via COMTEX/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced that Thomas P. Mac Mahon, chairman and chief executive officer, is scheduled to speak at the UBS Warburg Global Life Sciences Conference in New York City,

LabCorp's National Genetics Institute Receives FDA Approval for Nucleic Acid Tests for HCV and HIV-1

BURLINGTON, N.C., Sep 21, 2001 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced that its National Genetics Institute Inc. (NGI) had its Biologics License Applications for the UltraQual(TM) HCV RT-PCR and UltraQual(TM) HIV-1 RT-PCR assays approved

Laboratory Corporation of America(R) Holdings Announces Completion of Private Placement

BURLINGTON, N.C., Sept. 19 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today confirmed that it had previously completed its private placement of zero coupon convertible subordinated notes due 2021, the effect of which is expected to be accretive to 2001

Laboratory Corporation of America(R) Holdings Sets Terms of Zero Coupon Convertible Subordinated Notes

BURLINGTON, N.C., Sept. 6 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today the terms of its private placement of zero coupon convertible subordinated notes due 2021 with an aggregate principal amount at maturity of $650 million.

Laboratory Corporation of America(R) Holdings Announces Offering Of Zero Coupon Convertible Subordinated Notes

BURLINGTON, N.C., Sep 4, 2001 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced its intention, subject to market and other conditions, to raise approximately $435 million (excluding proceeds of an overallotment option, if any) through a private

Alpha Therapeutic Forms Alliance for Plasma Testing Laboratory; Agreement With National Genetics Institute and LabCorp Enhances Testing Operations

LOS ANGELES, Aug 28, 2001 (BW HealthWire) -- Alpha Therapeutic Corporation announced today that it has formed a laboratory management alliance with National Genetics Institute (NGI), a subsidiary of Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH), in which NGI/LabCorp will